MabVax Therapeutics Holdings, Inc., along with its affiliate, filed a joint plan of liquidation with related disclosure statement in the US Bankruptcy Court on November 27, 2019. As per the plan filed, Administrative Expense Claims of $0.33 million, Statutory Fees, Post-Confirmation Fees and Expenses and Professional Compensation Claims will be paid in full in cash on the effective date. DIP claims of $0.50 million will be paid in cash or any other treatment. Secured claims will either be paid by collateral securing or cash or any other treatment. Priority Tax Claims and non-tax claims will be paid in full in cash. 510(a), 510(b) and 510(c) subordinated Claims and inter-company claims will be deemed extinguished. General Unsecured Claims will be paid through pro rata share of available cash, while all equity interests shall be cancelled. The plan will be funded through sale of assets and available cash in hand.